Cytek Biosciences (CTKB) Cost of Revenue (2020 - 2026)

Cytek Biosciences has reported Cost of Revenue for 7 years, with the latest figure at $22.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 7.42% year-over-year to $22.9 million; the trailing twelve-month figure through Mar 2026 stood at $51.0 million (up 32.52% YoY), and the FY2025 full-year result was $49.4 million, up 0.66% from the prior year.
• Cost of Revenue for Q1 2026 stood at $22.9 million, up from -$18.3 million in the prior quarter.
• The five-year high for Cost of Revenue was $46.0 million in Q4 2023, with the low at -$18.3 million in Q4 2025.
• Historically, Cost of Revenue has averaged $15.7 million across 5 years, with a median of $16.0 million in 2023.
• Annual changes were most pronounced in 2023 — Cost of Revenue soared 2750.6% — and 2024, when it plunged 135.67%.
• Cytek Biosciences' Cost of Revenue stood at $38.9 million in 2022, then gained by 18.38% to $46.0 million in 2023, then slumped by 135.67% to -$16.4 million in 2024, then dropped by 11.75% to -$18.3 million in 2025, then surged by 224.78% to $22.9 million in 2026.
• The last three Cost of Revenue figures came in at $22.9 million (Q1 2026), -$18.3 million (Q4 2025), and $24.7 million (Q3 2025), per Business Quant data.